Biovica International AB
Biovica's capital structure is characterized by a high proportion of equity, with total equity of 96.64 million SEK and long-term debt of 7.83 million SEK, resulting in a debt-to-equity ratio of 0.08. The company maintains a strong liquidity position, with cash and equivalents of 79.41 million SEK and a current ratio of 3.11, indicating a robust ability to meet short-term obligations. Profitability metrics are negative, with a return on equity of -40.91% and a return on assets of -30.08%. These figures are significantly below the industry median for biotechnology firms, which typically exhibit positive returns during growth phases. The company reported a net loss of 39.53 million SEK, driven by a substantial operating loss of 41.49 million SEK. Geographically, Biovica's revenue is concentrated in a limited number of markets, with no detailed breakdown provided in the available data. The company's exposure to specific regions or customer segments is not disclosed, but its reliance on a narrow product portfolio increases vulnerability to market shifts. Growth prospects are mixed. The company's current fiscal year revenue is 18.99 million SEK, with analyst estimates projecting a significant increase to 40 million SEK in the next fiscal year. However, the company's operating cash flow is negative at -114.57 million SEK, and free cash flow is also negative at -37.31 million SEK, indicating ongoing cash burn despite revenue growth. Risk factors include the company's unprofitable operations and high cash burn rate, which could necessitate additional financing. The risk assessment indicates low dilution potential, but the company's liquidity risk is classified as low, supported by its strong cash reserves. No immediate filing-based liquidity or dilution flags were detected. Recent events include the publication of financial results showing continued losses and a lack of positive earnings surprises. The company has not issued new shares recently, and there are no indications of upcoming equity offerings or material regulatory changes affecting its operations.
Business. Biovica International AB develops and commercializes diagnostic products for the detection of neurodegenerative diseases, primarily through its proprietary biomarker technology.
Classification. Biovica is classified in the Biotechnology & Medical Research industry under the Healthcare economic sector, with a confidence level of 0.92 based on verified market data.
- Biovica maintains a strong liquidity position with a current ratio of 3.11 and 79.41 million SEK in cash and equivalents.
- The company is unprofitable, with a return on equity of -40.91% and a return on assets of -30.08%.
- Analysts project a significant revenue increase to 40 million SEK in the next fiscal year, but current operating cash flow is negative.
- The company's debt-to-equity ratio is low at 0.08, indicating a conservative capital structure.
- No immediate liquidity or dilution risks are flagged, but the company's unprofitability and cash burn rate remain concerns.
- --
- ## RATIONALES
- ```json
- No immediate filing-based liquidity or dilution flags were detected.